Trial reportAnnals of surgery2018
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
Trial report in Annals of surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 3 syntheses or guidelines pooled it, 187 citations in OpenAlex.
- Ultrasound-based predictive models for response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- The nodal positivity rate in breast pCR patients with initially, clinically node-negative breast cancer after neoadjuvant systemic therapy: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.Breast cancer research : BCR · 2024Trial
- The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial.Annals of surgical oncology · 2023Trial
- MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.Journal of surgical oncology · 2019Trial
- Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes.NPJ breast cancer · 2026Article
- Emerging technologies for monitoring breast cancer response to neoadjuvant chemotherapy: a systematic scoping review.Breast (Edinburgh, Scotland) · 2026Review
- Axillary response and diagnostic accuracy of imaging modalities after neoadjuvant chemotherapy for breast cancer (retrospective single center study).Frontiers in surgery · 2026Article
- Ensemble transformer-based multiple instance learning for predicting neoadjuvant chemotherapy response from breast cancer biopsy whole-slide images.Frontiers in oncology · 2026Article
- A nomogram integrating DCE-MRI imaging features and clinicopathological parameters for predicting pathological complete response in HER2-positive breast cancer.Frontiers in oncology · 2026Article
- Vacuum-Assisted Excision and Assessing Residual Tumor Burden in Patients With Breast Cancer Following Neoadjuvant Chemotherapy (A Pilot Study).International journal of breast cancer · 2026Article
- Development and validation of a nomogram incorporating YpT stage for predicting ypN0 using multicenter data in clinically node-positive breast cancer.Scientific reports · 2025Article
- Early prediction of neoadjuvant chemotherapy efficacy among patients with triple-negative breast cancer using an ultrasound-based radiomics nomogram.Diagnostic and interventional radiology (Ankara, Turkey) · 2025Article
- Image-guided biopsy of breast lesions-when to use what biopsy technique.Insights into imaging · 2025Article
- Minimally invasive biopsy technique predicting breast pathological complete response after neoadjuvant therapy for breast cancer.Gland surgery · 2025Article
- Multimodal prediction based on ultrasound for response to neoadjuvant chemotherapy in triple negative breast cancer.NPJ precision oncology · 2025Article
- Breast reconstruction and neoadjuvant radiotherapy (BRENAR) - study protocol for a multicenter, prospective, single-arm pilot study.International journal of surgery protocols · 2025Article
- Factors Associated with Nodal Positivity Following Neoadjuvant Systemic Therapy in Breast Cancer Patients Who are Initially Node-Negative on MRI.Annals of surgical oncology · 2025Article
- Is It Possible to Accurately Evaluate the Tumor Bed After Neoadjuvant Chemotherapy Using a 14G Tru-Cut Biopsy?Life (Basel, Switzerland) · 2025Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
22 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo determine the accuracy of fine-needle aspiration (FNA) and vacuum-assisted core biopsy (VACB) in assessing the presence of residual cancer in the breast after neoadjuvant systemic therapy (NST). SUMMARY BACKGROUND DATA: Pathologic complete response (pCR) rates after NST have improved dramatically, suggesting that surgery might be avoided in some patients. Safe avoidance of surgery would require accurate confirmation of no residual invasive/in situ carcinoma.
methodsForty patients with T1-3N0-3 triple-negative or HER2-positive cancer receiving NST were enrolled in this single-center prospective trial. Patients underwent ultrasound-guided or mammography-guided FNA and VACB of the initial breast tumor region before surgery. Findings were compared with findings on pathologic evaluation of surgical specimens to determine the performance of biopsy in predicting residual breast disease after NST.
resultsMedian initial clinical tumor size was 3.3 cm (range, 1.2-7.0 cm); 16 patients (40%) had biopsy-proven nodal metastases. After NST, median clinical tumor size was 1.1 cm (range, 0-4.2 cm). Nineteen patients (47.5%) had a breast pCR and were concordant with pathologic nodal status in 97.5%. Combined FNA/VACB demonstrated an accuracy of 98% (95% CI, 87%-100%), false-negative rate of 5% (95% CI, 0%-24%), and negative predictive value of 95% (95% CI, 75%-100%) in predicting residual breast cancer. VACB alone was more accurate than FNA alone (P = 0.011).
conclusionsAfter NST, image-guided FNA/VACB can accurately identify patients with a breast pCR. Based on these results, a prospective clinical trial has commenced in which breast surgery is omitted in patients with a breast pCR after NST according to image-guided biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.